• 1
    Hirsh J. Heparin. N Engl J Med 1991; 324: 15651574.
  • 2
    Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803813.
  • 3
    Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992; 3: 439449.
  • 4
    Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 2000; 83: 937943.
  • 5
    Ariens RA, Alberio G, Moia M, Mannucci PM. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 1999; 81: 203 207.
  • 6
    Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordoy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 1996; 76: 703709.
  • 7
    Bendz B, Hansen JB, Andersen TO, Ostergaard P, Sandset PM. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Br J Haematol 1999; 107: 756762.
  • 8
    Ariens RA, Faioni EM, Mannucci PM. Repeated release of the tissue factor pathway inhibitor. Thromb Haemost 1994; 72: 327328.
  • 9
    Eisenberg PR. Role of heparin in coronary thrombolysis. Chest 1992; 101: 131S139S.
  • 10
    Rosnoblet C, Vischer UM, Gerard RD, Irminger JC, Halban PA, Kruithof EK. Storage of tissue-type plasminogen activator in Weibel–Palade bodies of human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 17961803.
  • 11
    Hoppensteadt DA, Jeske W, Fareed J, Nicolaides AN. Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions. Int Angiol 1996; 15: 3946.
  • 12
    de Boer A, Kluft C, Dooijewaard G, et al. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. Thromb Haemost 1992; 68: 550555.
  • 13
    Hoppensteadt DA, Jeske W, Fareed J, Bermes EW. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995; 6 (Suppl 1): S57S64.
  • 14
    Schoemaker RC, Burggraaf J, Cohen AF. Assessment of hepatic blood flow using continuous infusion of high clearance drugs. Br J Clin Pharmacol 1998; 45: 463469.
  • 15
    Rowland M, Tozer TN. Constant-rate regimens. In Clinical Pharmacokinetics – Concepts and Applications, eds Rowland M, Tozer TN. Media, PA: Williams & Wilkins, 1995: 6682.
  • 16
    Kemme MJ, Burggraaf J, Schoemaker RC, et al. The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor. Clin Pharmacol Ther 2000; 67: 504511.
  • 17
    Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959972.
  • 18
    Bregengaard C, Nordfang O, Ostergaard P, et al. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454457.
  • 19
    Valentin S, Nordfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis 1993; 4: 713720.
  • 20
    Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 4: 661669.
  • 21
    Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ, Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 17731781.
  • 22
    Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S510S.
  • 23
    Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 20042010.
  • 24
    Kluft C, Jie AF, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost 1988; 59: 329332.
  • 25
    Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost 2001; 85: 824829.
  • 26
    Gori AM, Pepe G, Attanasio M, et al.Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 1999; 81: 589593.
  • 27
    Kojima T, Gando S, Kemmotsu O, et al. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor. J Cardiothorac Vasc Anesth 2001; 15: 6064.
  • 28
    Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 20452048.